Banyan Biomarkers Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Banyan Biomarkers General Information

Description

Developer of biomarkers designed to improve outcomes for patients suffering from neurological injuries and diseases. The company's biomarkers aim to rule out the need for CT scans in patients with a suspected mild traumatic brain injury that is based on actual data and not subjective interpretation, enabling physicians to identify and triage patients that need additional medical assistance and benefits by reducing radiation exposure from unnecessary CT scans.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 16470 West Bernardo Drive
  • Suite 100
  • San Diego, CA 92127
  • United States
Primary Industry
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 16470 West Bernardo Drive
  • Suite 100
  • San Diego, CA 92127
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Banyan Biomarkers Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Dec-2021 Completed Generating Revenue
8. Later Stage VC 16-Jun-2020 Completed Generating Revenue
7. Later Stage VC (Series A2) 06-Feb-2017 Completed Generating Revenue
6. Grant 23-Jul-2015 Completed Generating Revenue
5. Later Stage VC (Series A1) 24-Feb-2014 Completed Generating Revenue
4. Grant 30-Jan-2014 Completed Generating Revenue
3. Grant 03-Oct-2013 Completed Generating Revenue
2. Later Stage VC (Series A) 31-Jul-2013 $6M $6M Completed Generating Revenue
1. University Spin-Out 01-Jan-2002 Completed Startup
To view Banyan Biomarkers’s complete valuation and funding history, request access »

Banyan Biomarkers Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
Series A 8,823,529 $0.000100 8% $0.68 $0.68 1x $0.68 16.58%
To view Banyan Biomarkers’s complete cap table history, request access »

Banyan Biomarkers Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biomarkers designed to improve outcomes for patients suffering from neurological injuries and diseases. The
Biotechnology
San Diego, CA
18 As of 2022

Cambridge, MA

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Banyan Biomarkers Competitors (8)

One of Banyan Biomarkers’s 8 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
Foundation Medicine Formerly VC-backed Boston, MA
Kynexis Venture Capital-Backed Naarden, Netherlands
Cellmade Private Equity-Backed Ruffieux, France
NanoDx Venture Capital-Backed Southborough, MA
You’re viewing 5 of 8 competitors. Get the full list »

Banyan Biomarkers Patents

Banyan Biomarkers Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3532496-A1 Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods Pending 28-Oct-2016
JP-2022166139-A Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods Active 28-Oct-2016
JP-2024050716-A Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods Active 28-Oct-2016
WO-2018081649-A1 Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods Inactive 28-Oct-2016
WO-2015134551-A1 Micro rna markers for diagnosis of a neurological condition Inactive 03-Mar-2014 C12Q1/6883
To view Banyan Biomarkers’s complete patent history, request access »

Banyan Biomarkers Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Banyan Biomarkers Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Anzu Partners Venture Capital Minority
GE Aerospace Corporation
NFL Pension Plan Limited Partner
United States Department of War Government
To view Banyan Biomarkers’s complete investors history, request access »

Banyan Biomarkers FAQs

  • When was Banyan Biomarkers founded?

    Banyan Biomarkers was founded in 2002.

  • Where is Banyan Biomarkers headquartered?

    Banyan Biomarkers is headquartered in San Diego, CA.

  • What is the size of Banyan Biomarkers?

    Banyan Biomarkers has 18 total employees.

  • What industry is Banyan Biomarkers in?

    Banyan Biomarkers’s primary industry is Biotechnology.

  • Is Banyan Biomarkers a private or public company?

    Banyan Biomarkers is a Private company.

  • What is Banyan Biomarkers’s current revenue?

    The current revenue for Banyan Biomarkers is .

  • How much funding has Banyan Biomarkers raised over time?

    Banyan Biomarkers has raised $23.9M.

  • Who are Banyan Biomarkers’s investors?

    Anzu Partners, GE Aerospace, NFL Pension Plan, and United States Department of War have invested in Banyan Biomarkers.

  • Who are Banyan Biomarkers’s competitors?

    AnTolRx, Foundation Medicine, Kynexis, Cellmade, and NanoDx are some of the 8 competitors of Banyan Biomarkers.

  • When was Banyan Biomarkers acquired?

    Banyan Biomarkers was acquired on 01-Dec-2021.

  • Who acquired Banyan Biomarkers?

    Banyan Biomarkers was acquired by BioMérieux.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process